A Change for Generics is on the Horizon
Get an inside view of changes affecting the biosimilars market and understand what they may mean for the near future of your business. Don’t miss your free eBook from Generics Bulletin, presented in partnership with West Pharmaceuticals, Inc.
Chapters in your free eBook include:
- Samsung Bioepis Scoops First EU Lucentis Biosimilar As 2022 Date Looms
- Samsung Bioepis Goes After Lucentis With 40% Cheaper Byooviz Launch In US
- Coherus Shakes Up Ranibizumab Competition With First Interchangeable US Biosimilar
- Formycon Wins Endorsement For Second EU Lucentis Rival
- Stada And Xbrane Win EU Endorsement For Ranibizumab